These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28148677)

  • 1. The Moment that KRAS Mutation Started to Evolve into Precision Medicine in Metastatic Colorectal Cancer.
    Ushijima T; Yoshino T
    Cancer Res; 2016 Nov; 76(22):6443-6444. PubMed ID: 28148677
    [No Abstract]   [Full Text] [Related]  

  • 2. Precision Therapy in RAS Mutant Colorectal Cancer.
    Dienstmann R; Connor K; Byrne AT;
    Gastroenterology; 2020 Mar; 158(4):806-811. PubMed ID: 31972237
    [No Abstract]   [Full Text] [Related]  

  • 3. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
    Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
    Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.
    Malapelle U; Sgariglia R; De Stefano A; Bellevicine C; Vigliar E; de Biase D; Sepe R; Pallante P; Carlomagno C; Tallini G; Troncone G
    J Clin Pathol; 2015 Apr; 68(4):265-9. PubMed ID: 25609577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities.
    Porru M; Pompili L; Caruso C; Biroccio A; Leonetti C
    J Exp Clin Cancer Res; 2018 Mar; 37(1):57. PubMed ID: 29534749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized medicine and anti-EGFR antibody therapy in the treatment of metastatic colorectal cancer: KRAS and beyond.
    Chu E
    Oncology (Williston Park); 2014 Feb; 28(2):96. PubMed ID: 24701695
    [No Abstract]   [Full Text] [Related]  

  • 7. Polo-like Kinase 1 Inhibition in KRAS-Mutated Metastatic Colorectal Cancer.
    Stebbing J; Bullock AJ
    Clin Cancer Res; 2024 May; 30(10):2005-2007. PubMed ID: 38470499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between DPYD gene variation and KRAS wild type status in colorectal cancer.
    Kleist B; Kempa M; Meurer T; Poetsch M
    J Clin Pathol; 2016 Mar; 69(3):204-8. PubMed ID: 26281864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy.
    González NS; Marchese PV; Baraibar I; Ros J; Salvà F; Rodríguez M; Salvà C; Vaghi C; Alcaraz A; García A; Tabernero J; Élez E
    Expert Opin Investig Drugs; 2024 Jun; 33(6):613-625. PubMed ID: 38775361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are we ready to restrict EGFR therapy to quadruple-negative colorectal cancer?
    Hawkes E; Cunningham D
    Lancet Oncol; 2010 Nov; 11(11):1020-1. PubMed ID: 21051017
    [No Abstract]   [Full Text] [Related]  

  • 11. KRAS mutation screening in colorectal cancer: From paper to practice.
    Fakih MM
    Clin Colorectal Cancer; 2010 Jan; 9(1):22-30. PubMed ID: 20100685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting BRAF aberrations in advanced colorectal carcinoma: from bench to bedside.
    Abdel-Rahman O
    Future Oncol; 2016 Jan; 12(1):25-30. PubMed ID: 26616508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.
    Song QB; Wang Q; Hu WG
    World J Gastroenterol; 2015 Apr; 21(14):4365-72. PubMed ID: 25892888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should oncologists be aware in their clinical practice of KRAS molecular analysis?
    Santini D; Galluzzo S; Gaeta L; Zoccoli A; Riva E; Ruzzo A; Vincenzi B; Graziano F; Loupakis F; Falcone A; Muda AO; Tonini G
    J Clin Oncol; 2011 Mar; 29(8):e206-7; author reply e208-9. PubMed ID: 21263083
    [No Abstract]   [Full Text] [Related]  

  • 16. Metastatic colorectal cancer: current state and future directions.
    Fakih MG
    J Clin Oncol; 2015 Jun; 33(16):1809-24. PubMed ID: 25918280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pathologic diagnosis of colorectal cancer in the era of personalized therapy].
    Lai M
    Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):73-6. PubMed ID: 24742564
    [No Abstract]   [Full Text] [Related]  

  • 18. Letter to the editor: Worse prognosis caused by anti-EGFR treatment in advanced colorectal cancer patients with KRAS mutation.
    Yin P; Qiu Y; Li Q
    Int J Colorectal Dis; 2013 May; 28(5):733-4. PubMed ID: 22752244
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeted therapy in first line treatment of RAS wild type colorectal cancer.
    Formica V; Roselli M
    World J Gastroenterol; 2015 Mar; 21(10):2871-4. PubMed ID: 25780283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
    Temraz S; Mukherji D; Shamseddine A
    Int J Mol Sci; 2015 Sep; 16(9):22976-88. PubMed ID: 26404261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.